235 463

Cited 3 times in

Ferroportin and FBXL5 as Prognostic Markers in Advanced Stage Clear Cell Renal Cell Carcinoma

DC Field Value Language
dc.contributor.author박철근-
dc.contributor.author신상준-
dc.contributor.author조남훈-
dc.contributor.author최영득-
dc.contributor.author함원식-
dc.date.accessioned2021-12-28T17:50:06Z-
dc.date.available2021-12-28T17:50:06Z-
dc.date.issued2021-10-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/187288-
dc.description.abstractPurpose: Advanced stage clear cell renal cell carcinoma (ccRCC) involves a poor prognosis. Several studies have reported that dysfunctions in iron metabolism‒related proteins may cause tumor progression and metastasis of this carcinoma. In this study, we investigated the impact of the expression of iron metabolism‒related proteins on patient prognoses in advanced stage ccRCCs. Materials and methods: All of 143 advanced stage ccRCC specimens were selected following validation with double blind reviews. Several clinicopathological parameters including nuclear grade, perirenal fat invasion, renal sinus fat invasion, vascular invasion, necrosis, and sarcomatoid/rhabdoid differentiation were compared with the expression of ferroportin (FPN), and F-Box and leucine rich repeat protein 5 (FBXL5), by immunohistochemistry. FPN and FBXL5 mRNA level of ccRCC from The Cancer Genome Atlas database were also analyzed for validation. Results: FPN and FBXL5 immunohistochemistry showed membrane and cytoplasmic expression, respectively. Based on the H-score, cases were classified as low or high expression with a cutoff value of 20 for FPN and 15 for FBXL5, respectively. Low expression of FPN and FBXL5 were significantly associated with patient death (p=0.022 and p=0.005, respectively). In survival analyses, low expression of FPN and FBXL5 were significantly associated with shorter overall survival (p=0.003 and p=0.004, respectively). On multivariate analysis, low expression of FBXL5 (hazard ratio, 2.001; p=0.034) was significantly associated with shorter overall survival. Conclusion: FPN and FBXL5 can be used as potential prognostic markers and therapeutic targets for advanced stage ccRCC.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish, Korean-
dc.publisherOfficial journal of Korean Cancer Association-
dc.relation.isPartOfCANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleFerroportin and FBXL5 as Prognostic Markers in Advanced Stage Clear Cell Renal Cell Carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pathology (병리학교실)-
dc.contributor.googleauthorCheol Keun Park-
dc.contributor.googleauthorJayoon Heo-
dc.contributor.googleauthorWon Sik Ham-
dc.contributor.googleauthorYoung-Deuk Choi-
dc.contributor.googleauthorSang Joon Shin-
dc.contributor.googleauthorNam Hoon Cho-
dc.identifier.doi10.4143/crt.2021.031-
dc.contributor.localIdA05244-
dc.contributor.localIdA02105-
dc.contributor.localIdA03812-
dc.contributor.localIdA04111-
dc.contributor.localIdA04337-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.identifier.pmid33735560-
dc.subject.keywordClear cell renal cell carcinoma-
dc.subject.keywordF-Box and leucine rich repeat protein 5-
dc.subject.keywordFerroportin-
dc.subject.keywordImmunohistochemistry-
dc.subject.keywordPrognosis-
dc.contributor.alternativeNamePark, Cheol Keun-
dc.contributor.affiliatedAuthor박철근-
dc.contributor.affiliatedAuthor신상준-
dc.contributor.affiliatedAuthor조남훈-
dc.contributor.affiliatedAuthor최영득-
dc.contributor.affiliatedAuthor함원식-
dc.citation.volume53-
dc.citation.number4-
dc.citation.startPage1174-
dc.citation.endPage1183-
dc.identifier.bibliographicCitationCANCER RESEARCH AND TREATMENT, Vol.53(4) : 1174-1183, 2021-10-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.